Literature DB >> 18185926

Comparison of SLCO1B1 sequence variability among German, Turkish, and African populations.

Jessica Mwinyi1, Karla Köpke, Melanie Schaefer, Ivar Roots, Thomas Gerloff.   

Abstract

BACKGROUND: OATP1B1 is one of the key hepatocellular uptake transporters providing extraction of diverse compounds, including bile acids, xenobiotics, and a variety of drugs, from portal venous blood into the liver. Polymorphisms of the SLCO1B1 gene have been demonstrated to influence in vitro transport function and the pharmacokinetic profile of compounds.
OBJECTIVE: The goal of our study was the comparison of SLCO1B1 gene sequence variability in three ethnic groups as a basis for future genetic association studies.
METHODS: Eighteen exonic SLCO1B1 single nucleotide polymorphisms (SNPs) were genotyped by PCR and RFLP analysis in 300 German, 94 Turkish, and 115 African subjects. Calculation of pairwise linkage disequilibrium and estimation of population haplotype frequencies were carried out, and haplotype block structure was determined.
RESULTS: Only eight genotyped SNPs (c.388A>G, c.411G>A, c.463C>A, c.521T>C, c.571C>T, c.597C>T, c.1463G>>C, c.1929A>C) were found in at least one of our German, Turkish, or African samples. A total of 12 haplotypes with a frequency >or=1% in at least one of the three populations could be inferred. Between the Caucasian and African samples, significant differences in sequence variability were observed leading to a different haplotype profile in these populations.
CONCLUSION: Our results demonstrate a high sequence variability of OATP1B1 within different popuations. In the future, distinct haplotypes should be taken into account when studying the effect of OATP1B1 on drugs in different populations.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18185926     DOI: 10.1007/s00228-007-0409-y

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  26 in total

1.  A comparison of bayesian methods for haplotype reconstruction from population genotype data.

Authors:  Matthew Stephens; Peter Donnelly
Journal:  Am J Hum Genet       Date:  2003-10-20       Impact factor: 11.025

2.  A computer program for testing pairwise linkage disequilibria in subdivided populations.

Authors:  P Garnier-Gere; C Dillmann
Journal:  J Hered       Date:  1992 May-Jun       Impact factor: 2.645

3.  Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family.

Authors:  I Tamai; J Nezu; H Uchino; Y Sai; A Oku; M Shimane; A Tsuji
Journal:  Biochem Biophys Res Commun       Date:  2000-06-24       Impact factor: 3.575

4.  Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers.

Authors:  Jae-Yong Chung; Joo-Youn Cho; Kyung-Sang Yu; Jung-Ryul Kim; Dal-Seok Oh; Hye-Ryung Jung; Kyoung-Soo Lim; Ki-Ho Moon; Sang-Goo Shin; In-Jin Jang
Journal:  Clin Pharmacol Ther       Date:  2005-10       Impact factor: 6.875

5.  SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid.

Authors:  Marja K Pasanen; Mikko Neuvonen; Pertti J Neuvonen; Mikko Niemi
Journal:  Pharmacogenet Genomics       Date:  2006-12       Impact factor: 2.089

6.  A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters.

Authors:  B Hsiang; Y Zhu; Z Wang; Y Wu; V Sasseville; W P Yang; T G Kirchgessner
Journal:  J Biol Chem       Date:  1999-12-24       Impact factor: 5.157

7.  Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin.

Authors:  M K Pasanen; H Fredrikson; P J Neuvonen; M Niemi
Journal:  Clin Pharmacol Ther       Date:  2007-05-02       Impact factor: 6.875

8.  Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis.

Authors:  Takashi Nozawa; Miki Nakajima; Ikumi Tamai; Kumiko Noda; Jun-Ichi Nezu; Yoshimichi Sai; Akira Tsuji; Tsuyoshi Yokoi
Journal:  J Pharmacol Exp Ther       Date:  2002-08       Impact factor: 4.030

9.  Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics.

Authors:  Yohei Nishizato; Ichiro Ieiri; Hiroshi Suzuki; Miyuki Kimura; Kiyoshi Kawabata; Takeshi Hirota; Hiroshi Takane; Shin Irie; Hiroyuki Kusuhara; Yoko Urasaki; Akinori Urae; Shun Higuchi; Kenji Otsubo; Yuichi Sugiyama
Journal:  Clin Pharmacol Ther       Date:  2003-06       Impact factor: 6.875

Review 10.  Organic anion-transporting polypeptide (OATP) transporter family and drug disposition.

Authors:  R B Kim
Journal:  Eur J Clin Invest       Date:  2003-11       Impact factor: 4.686

View more
  21 in total

1.  Frequency of the SLCO1B1 388A>G and the 521T>C polymorphism in Tanzania genotyped by a new LightCycler®-based method.

Authors:  Eleni Aklillu; Sabina Mugusi; Eliford Ngaimisi; Michael Marcus Hoffmann; Sonja König; Victoria Ziesenitz; Gerd Mikus; Walter Emil Haefeli; Johanna Weiss
Journal:  Eur J Clin Pharmacol       Date:  2011-06-01       Impact factor: 2.953

Review 2.  Prediction of hepatic clearance in human from in vitro data for successful drug development.

Authors:  Masato Chiba; Yasuyuki Ishii; Yuichi Sugiyama
Journal:  AAPS J       Date:  2009-04-30       Impact factor: 4.009

3.  Inhibition of the organic anion-transporting polypeptide 1B1 by quercetin: an in vitro and in vivo assessment.

Authors:  Lan-Xiang Wu; Cheng-Xian Guo; Wang-Qing Chen; Jing Yu; Qiang Qu; Yao Chen; Zhi-Rong Tan; Guo Wang; Lan Fan; Qing Li; Wei Zhang; Hong-Hao Zhou
Journal:  Br J Clin Pharmacol       Date:  2012-05       Impact factor: 4.335

Review 4.  Pharmacogenetics of membrane transporters: an update on current approaches.

Authors:  Tristan M Sissung; Caitlin E Baum; C Tyler Kirkland; Rui Gao; Erin R Gardner; William D Figg
Journal:  Mol Biotechnol       Date:  2010-02       Impact factor: 2.695

5.  PharmGKB very important pharmacogene: SLCO1B1.

Authors:  Connie Oshiro; Lara Mangravite; Teri Klein; Russ Altman
Journal:  Pharmacogenet Genomics       Date:  2010-03       Impact factor: 2.089

6.  The impact of SLCO1B1 polymorphisms on the plasma concentration of lopinavir and ritonavir in HIV-infected men.

Authors:  Fabiana B Kohlrausch; Rita de Cássia Estrela; Paulo F Barroso; Guilherme Suarez-Kurtz
Journal:  Br J Clin Pharmacol       Date:  2010-01       Impact factor: 4.335

7.  Lack of association between SLCO1B1 polymorphism and the lipid-lowering effects of atorvastatin and simvastatin in Chinese individuals.

Authors:  Qiang Fu; Yan-Peng Li; Yuan Gao; Song-Hua Yang; Pei-Qi Lu; Min Jia; Li-Rong Zhang
Journal:  Eur J Clin Pharmacol       Date:  2012-12-22       Impact factor: 2.953

8.  No impact of SLCO1B1 521T>C, 388A>G and 411G>A polymorphisms on response to statin therapy in the Greek population.

Authors:  E Giannakopoulou; G Ragia; V Kolovou; A Tavridou; A D Tselepis; M Elisaf; G Kolovou; V G Manolopoulos
Journal:  Mol Biol Rep       Date:  2014-03-26       Impact factor: 2.316

Review 9.  Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME.

Authors:  Patricio Godoy; Nicola J Hewitt; Ute Albrecht; Melvin E Andersen; Nariman Ansari; Sudin Bhattacharya; Johannes Georg Bode; Jennifer Bolleyn; Christoph Borner; Jan Böttger; Albert Braeuning; Robert A Budinsky; Britta Burkhardt; Neil R Cameron; Giovanni Camussi; Chong-Su Cho; Yun-Jaie Choi; J Craig Rowlands; Uta Dahmen; Georg Damm; Olaf Dirsch; María Teresa Donato; Jian Dong; Steven Dooley; Dirk Drasdo; Rowena Eakins; Karine Sá Ferreira; Valentina Fonsato; Joanna Fraczek; Rolf Gebhardt; Andrew Gibson; Matthias Glanemann; Chris E P Goldring; María José Gómez-Lechón; Geny M M Groothuis; Lena Gustavsson; Christelle Guyot; David Hallifax; Seddik Hammad; Adam Hayward; Dieter Häussinger; Claus Hellerbrand; Philip Hewitt; Stefan Hoehme; Hermann-Georg Holzhütter; J Brian Houston; Jens Hrach; Kiyomi Ito; Hartmut Jaeschke; Verena Keitel; Jens M Kelm; B Kevin Park; Claus Kordes; Gerd A Kullak-Ublick; Edward L LeCluyse; Peng Lu; Jennifer Luebke-Wheeler; Anna Lutz; Daniel J Maltman; Madlen Matz-Soja; Patrick McMullen; Irmgard Merfort; Simon Messner; Christoph Meyer; Jessica Mwinyi; Dean J Naisbitt; Andreas K Nussler; Peter Olinga; Francesco Pampaloni; Jingbo Pi; Linda Pluta; Stefan A Przyborski; Anup Ramachandran; Vera Rogiers; Cliff Rowe; Celine Schelcher; Kathrin Schmich; Michael Schwarz; Bijay Singh; Ernst H K Stelzer; Bruno Stieger; Regina Stöber; Yuichi Sugiyama; Ciro Tetta; Wolfgang E Thasler; Tamara Vanhaecke; Mathieu Vinken; Thomas S Weiss; Agata Widera; Courtney G Woods; Jinghai James Xu; Kathy M Yarborough; Jan G Hengstler
Journal:  Arch Toxicol       Date:  2013-08-23       Impact factor: 5.153

Review 10.  Genetic factors affecting statin concentrations and subsequent myopathy: a HuGENet systematic review.

Authors:  William J Canestaro; Melissa A Austin; Kenneth E Thummel
Journal:  Genet Med       Date:  2014-05-08       Impact factor: 8.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.